Baseline characteristics of patients
| Characteristic . | Immunosuppression (GTH-AH 01/2010) N = 101∗ . | Emicizumab (GTH-AHA-EMI) N = 47∗ . | P value† . |
|---|---|---|---|
| Age in years | 74 (62-81) | 76 (66-80) | .683 |
| >74 | 49 (49%) | 26 (55%) | .441 |
| Female sex | 43 (43%) | 23 (49%) | .469 |
| FVIII activity in IU/dL | 1.4 (0.0-3.4) | 1.4 (0.0-5.6) | .319 |
| <1 | 46 (46%) | 18 (38%) | .407 |
| Inhibitor in BU/mL | 19 (8-71) | 12 (4-47) | .089 |
| >20 | 48 (48%) | 18 (38%) | .293 |
| WHO-PS >2 | 37 (37%) | 19 (40%) | .658 |
| Underlying disorders | |||
| Malignancy | 13 (13%) | 6 (13%) | .986 |
| Autoimmunity | 20 (20%) | 7 (15%) | .472 |
| Postpartum | 5 (5.0%) | 1 (2.1%) | .665 |
| Concomitant disorders | |||
| Cardiac disease | 38 (38%) | 13 (28%) | .235 |
| Renal disorders | 36 (36%) | 14 (30%) | .483 |
| Diabetes mellitus | 28 (28%) | 14 (30%) | .795 |
| Characteristic . | Immunosuppression (GTH-AH 01/2010) N = 101∗ . | Emicizumab (GTH-AHA-EMI) N = 47∗ . | P value† . |
|---|---|---|---|
| Age in years | 74 (62-81) | 76 (66-80) | .683 |
| >74 | 49 (49%) | 26 (55%) | .441 |
| Female sex | 43 (43%) | 23 (49%) | .469 |
| FVIII activity in IU/dL | 1.4 (0.0-3.4) | 1.4 (0.0-5.6) | .319 |
| <1 | 46 (46%) | 18 (38%) | .407 |
| Inhibitor in BU/mL | 19 (8-71) | 12 (4-47) | .089 |
| >20 | 48 (48%) | 18 (38%) | .293 |
| WHO-PS >2 | 37 (37%) | 19 (40%) | .658 |
| Underlying disorders | |||
| Malignancy | 13 (13%) | 6 (13%) | .986 |
| Autoimmunity | 20 (20%) | 7 (15%) | .472 |
| Postpartum | 5 (5.0%) | 1 (2.1%) | .665 |
| Concomitant disorders | |||
| Cardiac disease | 38 (38%) | 13 (28%) | .235 |
| Renal disorders | 36 (36%) | 14 (30%) | .483 |
| Diabetes mellitus | 28 (28%) | 14 (30%) | .795 |